The Efficacy and Improvement Methods of Multi-Kinase Inhibitors in the Treatment of Liver Cancer
DOI:
https://doi.org/10.61173/8m07qv49Keywords:
-Multi-kinase inhibitors, Liver cancer, Drug resistance, Clinical application, Targeted therapyAbstract
Liver cancer is a malignant tumor with an extremely high fatality rate worldwide, and traditional treatment methods have significant limitations. This thesis systematically explores the application of multi-kinase inhibitors in the treatment of liver cancer and deeply analyzes its dual mechanism of action: inhibiting tumor angiogenesis by blocking signaling pathways such as VEGF and PDGF, and simultaneously interfering with pathways such as MAPK to curb the proliferation of tumor cells. Based on key clinical research data such as SHARP and REFLECT, the survival benefits of monotherapy with drugs such as sorafenib and lenvatinib were elaborated in detail. The median survival period increased to 10.7-13.6 months, but the problems of drug resistance and adverse reactions were prominent. Combined immunotherapy and local treatment show the potential for synergistic enhancement. Studies have confirmed that screening for advantageous populations such as FGFR mutations through genetic testing can significantly improve the accuracy of treatment. This article aims to provide a comprehensive theoretical basis and innovative strategies for optimizing targeted therapy regimens for liver cancer and promoting clinical practice.
References
[1] Meng H., Weirong Y., Qinglin S., “Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer,” Frontiers in Genetics, vol. 13, 2022, pp. 1005658- 1005658.
[2] Jia-Ren W., Rui-Ning L., Chao-Yi H., et al., “Impact of antibiotics on the efficacy of immune checkpoint inhibitors in the treatment of primary liver cancer,” Liver Research, vol. 6, no. 3, 2022, pp. 175-180.
[3] Zhang W.-S., “Bioinformatics analysis of driver genes for lung cancer and its targeted drugs,” Ph.D. dissertation, Tianjin University, 2023. [Online]. Available: https://kns.cnki.net/ KCMS/detail/detail.aspx?dbcode=CDFD&dbname=CDFDTEM P&filename=1025223142.nh
[4] Cao M.-M., Li H., Sun D.-Q., He S.-Y., Yang F., Yan X.-X., et al., “Global epidemiological status of liver cancer in 2020,” Chinese Journal of Cancer Prevention and Treatment, no. 05, 2022, pp. 322–328.
[5] Li S.-H., Xia Y.-Q., Wang B.-Q., Chen Y.-H., “Effects and mechanism of c-Jun N-terminal kinase inhibitor D-JNKI1 on proliferation, invasion and apoptosis of human liver cancer HepG2 cells,” Chinese Journal of Biological Products, no. 03, 2025, pp. 302–311.
[6] Li J.-X., “Screening of tyrosine kinase inhibitor library reveals the activation mechanism of Merestinib-mediated T cell anti-tumor immunity,” Master’s thesis, Huazhong University of Science and Technology, 2024. [Online]. Available: https://kns. cnki.net/KCMS/detail/detail.aspx?dbcode=CMFD&dbname=C MFDTEMP&filename=1025255817.nh
[7] Zhang L., “What is targeted therapy for liver cancer,” Everyone’s Health, no. 08, 2024, p. 73.
[8] Li C.-E., Ma J., Wang Q.-Y., Yu J., “Meta-analysis of hypertension induced by small molecule tyrosine kinase inhibitors targeting VEGF pathway and its association with long-term prognosis in patients with solid tumors,” Chinese Journal of Hypertension (Chinese & English), no. 02, 2025, pp. 132–144.
[9] Valerio L., Matrone A., “Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer,” Exploration of Targeted Anti-Tumor Therapy, vol. 6, 2025, article no. 1002291.
[10] Mei Q. L., Can Q. S., Yan J., et al., “Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study,” Discover Oncology, vol. 14, no. 1, 2023, article no. 105.
[11] Wenchao Y., Xiaofang L., Jiana H., et al., “Efficacy and safety of immune checkpoint inhibitors combined with anti- VEGF therapy in the treatment of unresectable or advanced liver cancer: a systematic review,” Immunopharmacology and Immunotoxicology, vol. 45, no. 6, 2023, pp. 11–10.
[12] XiangYuan L., KongMing W., XingXing H., “Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets,” Journal of Experimental & Clinical Cancer Research: CR, vol. 40, no. 1, 2021, p. 172.
[13] S. M. B., Fabian P., W. A. J. S., et al., “Second interim analysis of RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodinerefractory differentiated thyroid cancer (RAI-R DTC),” Journal of Clinical Oncology, vol. 36, no. 15, 2018, p. 6081.
[14] S. M. B., Fabian P., W. A. J. S., et al., “Interim baseline characteristics from RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodinerefractory differentiated thyroid cancer (RAI-R DTC),” Journal of Clinical Oncology, vol. 35, no. 15, 2017, p. 6084.
[15] N. S., J. C., “Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib,” Biologics: Targets & Therapy, 2014, pp. 129–139.
[16] K. Thanki, M. E. Nicholls, A. Gajjar, A. J. Senagore, S. Qiu, C. Szabo, et al., “Consensus molecular subtypes of colorectal cancer and their clinical implications,” International Biology and Biomedical Journal, vol. 3, no. 3, 2017, pp. 105–111.
[17] J. Ros, I. Baraibar, E. Sardo, N. Mulet, F. Salva, G. Argiles, et al., “BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer,” Therapeutic Advances in Medical Oncology, vol. 13, 2021, article ID: 1758835921992974.
[18] M. K., S. K., S. A. M., “Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot,” Der Urologe. Ausg. A, vol. 46, no. 5, 2007, pp. 504–508, 510.
[19] Kuczyk M., Kruck S., Merseburger A., “Efficacy of multikinase inhibitors in the therapy of advanced renal cell carcinoma,” Der Urologe, vol. 46, no. 5, 2007, pp. 504–510.
[20] A. Narayanankutty, “PI3K/Akt/mTOR pathway as a therapeutic target for colorectal cancer: a review of preclinical and clinical evidence,” Current Drug Targets, vol. 20, no. 12, 2019, pp. 1217–1226.
[21] K. O. Kim, W. J. Park, Y. Jung, W. S. Lee, “Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on KRAS-mutated human colon cancer cell lines with different microsatellite instability,” Journal of Chemotherapy, vol. 32, no. 8, 2020, pp. 437–444.
[22] A. Sirvent, C. Benistant, J. Pannequin, L. Veracini, V. Simon, J. F. Bourgaux, et al., “Src family tyrosine kinasesdriven colon cancer cell invasion is induced by csk membrane delocalization,” Oncogene, vol. 29, no. 9, 2010, pp. 1303–1315.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
